During checkout, this product may be reported as "Out of Stock" with an Estimated Availability date. The Actual Availability date for this product may be earlier. Send inquiries regarding Actual Availability date, including the catalog number, to email@example.com.
The LanthaScreen®ATF2 (19-106) A549 cell line contains a fusion protein consisting of GFP and a fragment encoding for aa 19-106 of ATF2 under the control of a CMV promotor. A549 is a lung carcinoma cell line which shows inducible activation of JNK by number of different ligands, such as TNF and EGF, which leads to the transient phosphorylation of GFP-ATF2 (19-106). This LanthaScreen®cell line therefore allows the analysis of JNK activity using GFP-ATF2 phosphorylation as readout. The GFP-ATF2 (19-106) construct was transfected into A549 cells using Lipofectamine™2000, followed by selection with Blasticidin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker. This cell line is validated for EC50 and Z' under optimized conditions using TNF as ligand for JNK mediated GFP-ATF2 (19-106) phosphorylation. This cell line has been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and assay development time. Additional information using alternate stimuli is also available. Academic and non-profit customers, please inquire for special pricing.
For Research Use Only. Not for use in diagnostic procedures.
Contents & Storage
LanthaScreen™ Cellular assays are shipped on dry ice. Store in liquid nitrogen immediately upon receipt, or thaw for immediate use.